Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | MC3R | P41968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679077 | 0.94 | FNTA (0.42) | FNTAFNTBPGGT1BCA1CA2 | |
| SCHEMBL19079056 | 0.88 | TDP1 (0.44) | FNTAFNTBPGGT1BTDP1PAX8 | |
| SCHEMBL29679161 | 0.86 | TDP1 (0.42) | FNTAFNTBPGGT1BCA1CA2 | |
| SCHEMBL29679269 | 0.86 | CA1 (0.42) | CA1CA2TDP1PAX8FOLH1 | |
| SCHEMBL14680406 | 0.86 | TDP1 (0.39) | FNTAFNTBPGGT1BCA1CA2 | |
| SCHEMBL31514305 | 0.85 | PLG (0.43) | FNTAFNTBPGGT1BCA1CA2 | |
| SCHEMBL19065173 | 0.85 | TDP1 (0.49) | TDP1PAX8FOLH1MAPT | |
| SCHEMBL19065174 | 0.85 | TDP1 (0.49) | TDP1PAX8FOLH1MAPT | |
| SCHEMBL31514296 | 0.85 | TDP1 (0.49) | TDP1PAX8FOLH1MAPT | |
| SCHEMBL29679276 | 0.85 | FOLH1 (0.46) | CA1CA2CTSSCTSKTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388144-B2 | Radiolabeled prostate specific membrane antigen inhibitors | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150078998-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2015-03-19 | — | — | US | disclosed |
| US-8926944-B2 | Radiolabeled prostate specific membrane antigen inhibitors | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130034494-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130034494-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, PSMA1 | FNTA 202/4885FNTB 94/4885PGGT1B 306/4885 |
| US-20150078998-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, PSMA2 | FNTA 295/4885FNTB 63/4885PGGT1B 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.